Immune Specific and Tumor-Dependent mRNA Vaccines for Cancer Immunotherapy: Reprogramming Clinical Translation into Tumor Editing Therapy

被引：3

作者：

Katopodi, Theodora ^{[1
]}

Petanidis, Savvas ^{[1
,2
]}

Grigoriadou, Eirini ^{[1
]}

Anestakis, Doxakis ^{[3
]}

Charalampidis, Charalampos ^{[3
]}

Chatziprodromidou, Ioanna ^{[4
]}

Floros, George ^{[5
]}

Eskitzis, Panagiotis ^{[6
]}

Zarogoulidis, Paul ^{[7
]}

Koulouris, Charilaos ^{[7
]}

Sevva, Christina ^{[7
]}

Papadopoulos, Konstantinos ^{[7
]}

Roulia, Panagiota ^{[7
]}

Mantalovas, Stylianos ^{[7
]}

Dagher, Marios ^{[7
]}

Karakousis, Alexandros Vasileios ^{[7
]}

Varsamis, Nikolaos ^{[8
]}

Vlassopoulos, Konstantinos ^{[9
]}

Theodorou, Vasiliki ^{[9
]}

Mystakidou, Chrysi Maria ^{[9
]}

Katsios, Nikolaos Iason ^{[10
]}

Farmakis, Konstantinos ^{[11
]}

Kosmidis, Christoforos ^{[7
]}

机构：

[1] Aristotle Univ Thessaloniki, Dept Med, Lab Med Biol & Genet, Thessaloniki 54124, Greece

[2] IM Sechenov First Moscow State Med Univ, Dept Pulmonol, Moscow 119992, Russia

[3] Univ Cyprus, Med Sch, Dept Anat, CY-1678 Nicosia, Cyprus

[4] Univ Patra, Med Sch, Dept Publ Hlth, Patras 26500, Greece

[5] Univ Thessaly, Dept Elect & Comp Engn, Volos 38334, Greece

[6] Univ Western Macedonia, Dept Obstet, Kozani 50100, Greece

[7] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Dept Surg 3, Thessaloniki 55236, Greece

[8] European Interbalkan Med Ctr, Thessaloniki 55535, Greece

[9] Aristotle Univ Thessaloniki, Fac Hlth Sci, Dept Med, Thessaloniki 54124, Greece

[10] Univ Ioannina, Fac Hlth Sci, Med Sch, Ioannina 45110, Greece

[11] Aristotle Univ Thessaloniki, Gen Hosp Thessaloniki G Gennimatas, Pediat Surg Clin, Thessaloniki 54635, Greece

来源：

PHARMACEUTICS | 2024年 / 16卷 / 04期

关键词：

mRNA vaccines; reprogramming; immunoediting; immunotherapy; CODON OPTIMALITY; INNATE; MECHANISMS; CHALLENGES; RESISTANCE; INTERFACE;

D O I：

10.3390/pharmaceutics16040455

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Extensive research into mRNA vaccines for cancer therapy in preclinical and clinical trials has prepared the ground for the quick development of immune-specific mRNA vaccines during the COVID-19 pandemic. Therapeutic cancer vaccines based on mRNA are well tolerated, and are an attractive choice for future cancer immunotherapy. Ideal personalized tumor-dependent mRNA vaccines could stimulate both humoral and cellular immunity by overcoming cancer-induced immune suppression and tumor relapse. The stability, structure, and distribution strategies of mRNA-based vaccines have been improved by technological innovations, and patients with diverse tumor types are now being enrolled in numerous clinical trials investigating mRNA vaccine therapy. Despite the fact that therapeutic mRNA-based cancer vaccines have not yet received clinical approval, early clinical trials with mRNA vaccines as monotherapy and in conjunction with checkpoint inhibitors have shown promising results. In this review, we analyze the most recent clinical developments in mRNA-based cancer vaccines and discuss the optimal platforms for the creation of mRNA vaccines. We also discuss the development of the cancer vaccines' clinical research, paying particular attention to their clinical use and therapeutic efficacy, which could facilitate the design of mRNA-based vaccines in the near future.

引用

页数：18

共 97 条

[1]

Adamik J, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abo4632

[2] Codon optimality-mediated mRNA degradation: Linking translational elongation to mRNA stability [J].

Bae, Haneui ;

Coller, Jeff .

MOLECULAR CELL, 2022, 82 (08) :1467-1476

[3] Therapeutic targeting of tumour myeloid cells [J].

Barry, Simon T. ;

Gabrilovich, Dmitry I. ;

Sansom, Owen J. ;

Campbell, Andrew D. ;

Morton, Jennifer P. .

NATURE REVIEWS CANCER, 2023, 23 (04) :216-237

[4] Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma [J].

Batich, Kristen A. ;

Mitchell, Duane A. ;

Healy, Patrick ;

Herndon, James E., II ;

Sampson, John H. .

CLINICAL CANCER RESEARCH, 2020, 26 (20) :5297-5303

[5] Are There Hidden Genes in DNA/RNA Vaccines? [J].

Beaudoin, Christopher A. ;

Bartas, Martin ;

Volna, Adriana ;

Pecinka, Petr ;

Blundell, Tom L. .

FRONTIERS IN IMMUNOLOGY, 2022, 13

[6] Vaccinology: time to change the paradigm? [J].

Benn, Christine Stabell ;

Fisker, Ane B. ;

Rieckmann, Andreas ;

Sorup, Signe ;

Aaby, Peter .

LANCET INFECTIOUS DISEASES, 2020, 20 (10) :E274-E283

[7] RALA-mediated delivery of FKBPL nucleic acid therapeutics [J].

Bennett, Rachel ;

Yakkundi, Anita ;

McKeen, Hayley D. ;

McClements, Lana ;

McKeogh, Thomas J. ;

McCrudden, Cian M. ;

Arthur, Kenneth ;

Robson, Tracy ;

McCarthy, Helen O. .

NANOMEDICINE, 2015, 10 (19) :2989-3001

[8] mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients [J].

Bidram, Maryam ;

Zhao, Yue ;

Shebardina, Natalia G. ;

Baldin, Alexey V. ;

Bazhin, Alexandr V. ;

Ganjalikhany, Mohamad Reza ;

Zamyatnin, Andrey A. ;

Ganjalikhani-hakemi, Mazdak .

VACCINES, 2021, 9 (10)

[9] Proximity Ligation Assays for In Situ Detection of Innate Immune Activation: Focus on In Vitro-Transcribed mRNA [J].

Blanchard, Emmeline L. ;

Loomis, Kristin H. ;

Bhosle, Sushma M. ;

Vanover, Daryll ;

Baumhof, Patrick ;

Pitard, Bruno ;

Zurla, Chiara ;

Santangelo, Philip J. .

MOLECULAR THERAPY-NUCLEIC ACIDS, 2019, 14 :52-66

[10] Targeting macrophages: therapeutic approaches in cancer [J].

Cassetta, Luca ;

Pollard, Jeffrey W. .

NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (12) :887-904

← 1 2 3 4 5 6 7 8 9 10 →